Differential regulation of BACE1 expression by oxidative and nitrosative signals by Kwak, Young-Don et al.
RESEARCH ARTICLE Open Access
Differential regulation of BACE1 expression by
oxidative and nitrosative signals
Young-Don Kwak
1, Ruishan Wang
1, Jing Jing Li
1, Yun-Wu Zhang
2, Huaxi Xu
3, Francesca-Fang Liao
1*
Abstract
Background: It is well established that both cerebral hypoperfusion/stroke and type 2 diabetes are risk factors for
Alzheimer’s disease (AD). Recently, the molecular link between ischemia/hypoxia and amyloid precursor protein
(APP) processing has begun to be established. However, the role of the key common denominator, namely nitric
oxide (NO), in AD is largely unknown. In this study, we investigated redox regulation of BACE1, the rate-limiting
enzyme responsible for the b-cleavage of APP to Ab peptides.
Results: Herein, we studied events such as S-nitrosylation, a covalent modification of cysteine residues by NO, and
H2O2-mediated oxidation. We found that NO and H2O2 differentially modulate BACE1 expression and enzymatic
activity: NO at low concentrations (<100 nM) suppresses BACE1 transcription as well as its enzymatic activity while
at higher levels (0.1-100 μM) NO induces S-nitrosylation of BACE1 which inactivates the enzyme without altering its
expression. Moreover, the suppressive effect on BACE1 transcription is mediated by the NO/cGMP-PKG signaling,
likely through activated PGC-1a.H 2O2 (1-10 μM) induces BACE1 expression via transcriptional activation, resulting
in increased enzymatic activity. The differential effects of NO and H2O2 on BACE1 expression and activity are also
reflected in their opposing effects on Ab generation in cultured neurons in a dose-dependent manner.
Furthermore, we found that BACE1 is highly S-nitrosylated in normal aging brains while S-nitrosylation is markedly
reduced in AD brains.
Conclusion: This study demonstrates for the first time that BACE1 is highly modified by NO via multiple
mechanisms: low and high levels of NO suppress BACE1 via transcriptional and post translational regulation, in
contrast with the upregulation of BACE1 by H2O2-mediated oxidation. These novel NO-mediated regulatory
mechanisms likely protect BACE1 from being further oxidized by excessive oxidative stress, as from H2O2 and
peroxynitrite which are known to upregulate BACE1 and activate the enzyme, resulting in excessive cleavage of
APP and Ab generation; they likely represent the crucial house-keeping mechanism for BACE1 expression/activation
under physiological conditions.
Background
It is well established that both cerebral hypoperfusion/
stroke and type 2 diabetes are risk factors for Alzhei-
mer’s disease (AD) [1-4]. Oxidative and nitrosative stres-
ses are common denominators for these age-related
diseases [5]. Oxidative stress is associated with b-amy-
loid peptide (Ab) accumulation in the brains of AD
patients [6,7]. Ab is generated by sequential proteolytic
cleavages of the transmembrane amyloid precursor pro-
tein (APP) by two membrane-bound proteases, b-
secretase (BACE1) and the g-secretase complex com-
posed of presenilin 1 (PS1), nicastrin, APH-1 and PEN-2
[8-10]. In AD brains, the specific regions affected by Ab
deposition correlate with increased BACE1 protein levels
and activity [11-15]. Together with the observation that
amyloid pathology was diminished in mice deficient in
BACE1 [16,17], these findings strongly suggest that
BACE1 elevation leads to enhanced Ab production and
deposition in AD. Given the central role of Ab in AD
pathogenesis and the fact that BACE1 is the rate-limit-
ing enzyme in APP processing and Ab generation,
BACE1 remains one of the most important therapeutic
targets for treating AD.
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tightly regulated at both the transcriptional and transla-
tional levels [18,19]. A number of transcriptional factors
have been identified that positively or negatively regulate
BACE1 gene expression under both basal and cell-stressed
conditions, such as inflammation [20-22]. Some studies
suggest that BACE1 is regulated by specific microRNAs,
post-transcriptionally [23-25]. In addition to inflammation,
other conditions have also been shown capable of causing
increased BACE1 expression in the brain, including oxida-
tive stress, traumatic brain injury [26], hypoxia and ische-
mia [27,28]. Neuronal cells exposed to oxidizing agents
such as H2O2 and 4-HNE (4-hydroxynonenal) also show
increased BACE1 expression [29,30]. Moreover, injury and
stress-induced increases in lipid peroxidation were
recently demonstrated to be responsible for upregulation
of BACE1 expression in the brain of a genetic mouse
model [31]. While the molecular mechanism underlying
ischemia/hypoxia-induced BACE1 activation and APP
processing has been extensively studied [32-34], the mole-
cular basis of oxidative/nitrosative signal-mediated BACE1
regulation is virtually unknown.
T h ed i f f u s i b l eg a s e o u sn i t r i co x i d e( N O )m o l e c u l ei s
generated by activated nitric oxide synthase (NOS) which
exists in at least three isoforms (neuronal nNOS, inducible
iNOS and endothelial eNOS). NO is known to have pleio-
tropic physiological and pathological effects depending on
the target tissue and cell type [35,36]. For instance, in
blood vessels NO functions as a vasodilator, while in the
nervous system NO acts as a neurotransmitter. However,
if produced in excess and in the appropriate redox state,
NO can be neurotoxic. It is well-accepted that NO
released from eNOS is protective by promoting vasodila-
tion while NO produced from overactivation of nNOS or
iNOS under inflammatory conditions (which generates
over 1000-fold more NO compared to constitutive nNOS
and eNOS) is deleterious [37,38]. Often, the damage
caused by excessive amounts of NO is affected through a
neurotoxic derivative named peroxynitrite formed by com-
bining with superoxide anions (O2) .S i g n a l i n gb yN Oi s
transduced mainly by targeted modifications of critical
cysteine residues in proteins, including S-nitrosylation and
S-oxidation, as well as by lipid and tyrosine nitration
[39,40]. S-nitrosylation, the covalent modification of a
thiol group by NO, probably represents the major
mechanism of NO signaling [41-44]; it plays a critical role
in fine-tuning a number of important molecules in the
CNS related to cell death, protein folding and degradation
[45,46]. We recently demonstrated that the PI3K/Akt sig-
naling pathway, which is arguably the most important
pro-survival pathway in neurons, is sensitive to this redox
regulation; S-nitrosylation and NO-mediated regulation of
PTEN represents a novel and crucial mechanism to acti-
vate PI3K/Akt signaling [47].
In this study, we investigated NO-mediated regulation
of BACE1 and compared it to that of H2O2. We specu-
lated that the dual functions of NO may exert differen-
tial effects on BACE1 regulation. Indeed, we observed
different effects from NO at low and high levels and
found that the two conditions also regulate BACE1 dif-
ferently from H2O2-mediated oxidation; these may
represent the actual redox regulation of BACE1 during
the various stages of AD pathogenesis.
Results
Exogenous and endogenous NO donors induce S-
nitrosylation of BACE1 in cultured neurons
Using biotin-switch assays [48], we found that S-nitrosy-
lation of BACE1 (SNO-BACE1) can be rapidly induced
in primary cultured cortical neurons treated with the
physiological NO donor S-nitrosocysteine (SNOC) in a
dose-dependent manner. Detectable nitrosylation was
induced by 100 nM SNOC with a plateau seen at 100 μM
of SNOC. Notably, specific nitrosylation occurred only
on the mature form of BACE1 (upper band, Figure 1A).
We therefore only present data for the mature BACE1 in
most figures and Western blot analyses. This was also
confirmed by a more quantitative fluorescent assay
(DAN assay, [49]) using purified recombinant BACE1
(data not shown). Additional neurotoxic compounds that
induce NO generation, such as ionomycin, also induced
robust SNO-BACE1 within minutes (Figure 1B) which
lasted for several hours, even after the NO donors were
removed from the cultured media. Furthermore, we
found that the induced BACE1 nitrosylation was dimin-
ished by DTT treatment (1 mM, data not shown).
SNOC displays differential effects on BACE1 protein levels
at low and high concentrations
We then examined the effects of SNOC on BACE1 pro-
tein levels and surprisingly found that SNOC exerts dif-
ferent effects at low and high concentrations.
Specifically, SNOC at lower than 100 nM reduced
BACE1 expression by ~ 50% (Figure 2A) which was
restored to normal basal levels at SNOC concentrations
higher than 100 nM. Interestingly, SNOC at concentra-
tions higher than 100 nM exerted no effect on BACE1
protein expression levels (Figure 2B), The endogenous
NO induced by ionomycin showed no effect on BACE1
at various concentrations (Figure 2C). In contrast, H2O2
induced BACE1 expression at concentrations as low as
10 μM in a dose-dependent manner (Figure 2D).
Low NO levels suppress BACE1 transcription which is
likely mediated through cGMP-PKG-upregulated PGC-
1alpha
It was previously shown that oxidative stressors such as
H2O2 can upregulate BACE1 at the transcriptional level
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centration NO-mediated BACE1 suppression is effected
through transcriptional inhibition, we conducted quanti-
tative RT-PCR on endogenous BACE1 in rat primary
neurons treated with various concentrations of SNOC.
We found that the BACE1 messages were reduced in a
dose-dependent manner from 0.1-100 nM and then
slowly restored from 1-100 μM to their basal levels (Fig-
ure 3A). The maximum reduction of BACE1 messages
was 2-fold, seen between 10-100 nM, which was consis-
tent with the 50% reduction in BACE1 protein levels.
We therefore believe that the low-concentration NO-
mediated BACE1 suppression is mainly effected through
transcriptional regulation.
Since NO signaling at low NO concentration is usually
mediated by the classic cGMP activated PKG pathway,
we then tested the effect of a potent NO/cGMP-PKG
inhibitor, 1H-[1.2.4]Oxadiazolo[4,3-a]quinoxalin-1-one
(ODG), and showed that it abolished the suppressive
effect of low NO on BACE1 transcription (Figure 3B).
Furthermore, we tested the potential role of the coacti-
vator of PPARg,n a m e dP G C - 1 a,w h i c hi sk n o w nt ob e
upregulated by low-concentration NO-cGMP signals
Figure 2 Effect of nitrosative and oxidative stresses on BACE1
protein levels. To examine differential effects of nitrosative and
oxidative stresses on BACE1 protein levels, various concentrations of
SNOC (0, 0.001, 0.01, 0.1, 1, 10, 50, 100, 200, and 300 μM) (A and B),
Ionomycin (0, 0.1, 0.3, 1, 3, 10 μM) (C) and H2O2 (0, 3, 10, 30, 100,
300 μM) (D) were added to primary rat cortical neurons for 1 hr.
Then, BACE1 protein level was measured by probing BACE1 with a
specific monoclonal antibody (5D3). While lower concentrations of
SNOC downregulated the BACE1 protein level, high concentrations
of SNOC showed no effect on BACE1 protein levels (A and B).
BACE1 expression level was not affected by endogenous NO
induced by ionomycin (C). However, lower concentration of H2O2
significantly upregulated BACE1 protein levels (D).
Figure 3 Low NO concentrations suppress BACE1 transcription,
which is likely mediated through cGMP-PKG-upregulated PGC-
1a. (A) Effect of nitrosative stress on BACE1 mRNA levels was
examined by qRT-PCR. Lower concentrations of SNOC inhibited
while higher concentrations of SNOC had no effect on BACE1
transcription. (B) Effect of cGMP inhibitor, 1H-[1.2.4]Oxadiazolo[4,3-a]
quinoxalin-1-one (ODG, Sigma) in BACE1 transcription. (C) Effect of
NO on PGC-1a mRNA levels. (D) Effect of PGC-1a overexpression on
the promoter activity BACE1 from both human and rat origins, as
assessed by luciferase assay with/without transfection of PGC-1a. (E)
Effect of PGC-1a on BACE1 mRNA levels was assessed with qRT-
PCR.
Figure 1 Exogenous and endogenous NO donors induce S-
nitrosylation of BACE1 in cultured PRCN neurons. (A)
Nitrosylation of BACE1 by SNOC was detected with biotin-switch
assays: After exposure to SNOC (100 μM) for 30 min, to detect S-
nitrosylated cystein residues, the free cysteine residues of BACE1
were first masked by methylthiolation with MMTS. Nitrosothiols
were then selectively reduced by ascorbate to reform free thiol
groups, which reacted with biotin-HPDH. Subsequently, biotin-HPDH
conjugated proteins can be precipitated by streptavidin beads. In
this experiment, MMTS was not added, to serve as a positive
control, since all the cysteine residues in BACE1 can react with
biotin-HPDP (last lane). Samples not treated with ascorbate (third
lane) were used as a negative control due to the lack of reactive
cysteine residues to biotin-HPDH. (B) Effect of Ca
2++ ionophore,
ionomycin (1 μM), on SNO-BACE1 was examined at various time
points (0, 5, 10, 15, and 30 min) by biotin-switch assay.
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the mRNA levels of PGC-1a under various SNOC con-
centrations and found an inverse correlation between
the mRNA levels of BACE1 and PGC-1a (Figure 3C).
Because PPARg has been suggested to suppress BACE1
via its responsive element (PPRE, [53]), it is possible
that the upregulated PGC-1a is involved in BACE1
transcriptional control. Indeed, we show here that over-
expression of PGC-1a can downregulate BACE1 tran-
scription, measured by its effect on endogenous BACE1
message levels (Figure 3D); a similar effect was also seen
on the transfected rat BACE1 promoter using a lucifer-
ase assay (Figure 3E). Taken together, these results
s t r o n g l ys u g g e s tt h a tP G C - 1 a may be the major factor
mediating the BACE1 suppression in response to
cGMP-PKG signaling.
SNOC and H2O2 have opposing effects on BACE1
enzymatic activity and subsequent Ab generation
Since S-nitrosylation occurs at critical Cys residues
which often leads to alteration of the structure and
function of the target proteins, we examined BACE1
enzymatic activity upon SNOC and H2O2 treatments.
Interestingly, SNOC-BACE1 shows reduced enzymatic
activity while oxidized BACE1 exhibits enhanced activ-
ity; assays were performed with a commercial kit using
both cell lysates and purified recombinant protein (Fig-
u r e4 A ) .A c c o r d i n g l y ,S N O Ca n dH 2O2 display oppo-
site effects on Ab generation, as determined by IP-
Westerns using an antibody specific to Ab (6E10).
Consistent with the dose-dependent effects of H2O2 on
BACE1 transcription, H2O2 also shows an effect
dependent on the same dosages that induce BACE1
and Ab generation, with a maximum effect seen at 10
μM( F i g u r e4 B ) .
SNO-BACE1 levels decrease in late stage AD brains which
inversely correlates with BACE1 protein levels
We next investigated whether S-nitrosylation of BACE1
occurred in vivo in neurodegenerative disorders asso-
ciated with high levels of nitrosative stress, such as
stroke and AD. We included in our tests those speci-
mens taken from autopsy patients diagnosed at an early
stage of AD called mild cognitive impairment (MCI)
and compared them to age-matched control brain speci-
mens (i.e., patients died from disorders not related to
CNS). We chose to examine the entorhinal cortices, the
most vulnerable region in AD brains. The patient cohort
and information are summarized in the additional table.
From semi-quantitative profiling of SNO-BACE1 and
total BACE1 in 18 human brains, we found that SNO-
BACE1 was at high levels in control and MCI samples
and was markedly reduced in the late stage AD brains
(Figure 5).
Discussion
It is widely accepted that oxidative stress is one of the
earliest changes that occurs in the pathogenesis of AD,
arising from the imbalance between increased produc-
tion of reactive oxygen and nitrogen species and
impaired antioxidant defenses, as reflected in the
Figure 4 SNOC and H2O2 have opposing effects on BACE1
enzymatic activity and subsequent Ab generation. (A and B)
Effect of nitrosative and oxidative stresses on BACE1 activity was
measured by a fluorescent based b-secretase activity assay kit
(Sigma). Different doses of SNOC and H2O2 were added to N2a-695
stable cells expressing human APP695 proteins, for 1 hr.
Subsequently, cells were lysed by lysis buffer for measurement of
BACE1 activity. (C) For further investigation of the effect of SNOC
and H2O2 on Ab generation, conditioned media was collected after
4 hrs incubation with OPTI-MEM media from cells treated with
various concentrations of SNOC and H2O2 for 1 hr. Then, secreted
Ab peptides were immunoprecipitated with 6E10 antibody and
protein G/A beads to measure secreted Ab peptides.
Figure 5 SNO-BACE1 levels decrease in late stage AD brains
which inversely correlates with BACE1 protein levels. (A) SNO-
BACE1 levels were detected by immunoblot analysis following
biotin-switch assays in NC, MCI, and AD patient brain samples. Total
BACE1 levels were detected by Western blot analysis. (B)
Quantification of the Western blots using densitometry analysis
reveals a statistically significant elevation of SNO-BACE1 levels in AD
brains compared to NC and MCI brains ** indicates P < 0.005.
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detected in MCI and AD brains [39,40]. In this work,
we present in vitro and in vivo evidence of NO-
mediated regulation of BACE1. We are the first to
demonstrate that NO, at different levels, can exert dif-
ferential regulation on BACE1: at low levels, NO sup-
presses BACE1 transcription while at modest to high
levels, NO induces S-nitrosylation of BACE1 and inacti-
vates the enzyme. Furthermore, we show that S-nitrosy-
lation of BACE1 occurs in normal aging and MCI
brains but is significantly diminished in late stage AD
brains. Given the central role of Ab in AD pathogenesis
and the fact that BACE1 is the rate-limiting enzyme in
APP processing and Ab generation, the redox regulation
of BACE1 identified herein may represent a novel and
crucial mechanism for keeping BACE1 at physiological
levels/activity.
The multifaceted actions of the NO group can be clas-
sified into two categories: classic NO-mediated/cGMP-
dependent actions and reactive nitrogen species-
mediated/cGMP-independent actions. The cGMP-depen-
dent actions often play critical roles in a variety of phy-
siological processes, including NO-mediated vasodilation.
In contrast, cGMP-independent actions are more fre-
quently postulated to be involved in the pathological
responses which are primarily effected by nitrosative
post-translational modifications of proteins such as S-
nitrosylation and tyrosine nitration [41-46]. Although
low nanomolar concentrations of NO donors are suffi-
cient to elicit cGMP-dependent signals, 50-100 μMo f
NO donors is required for S-nitrosylation-mediated
alterations of protein function in cultured cells [37,38,54].
Based on these ideas, we speculate that the NO gener-
ated by different NOSs exerts differential modulations of
BACE1. For example, the low levels of NO that result in
suppression of BACE1 transcription may represent the
NO released from vascular eNOS. Although it is difficult
to measure the precise concentration of the bioreactive
NO in the blood circulation of a healthy vertebrate, the
decreased BACE1 transcription induced at the 10-100 nM
range of NO donors may be related to the protective
actions caused by the release of NO from vascular eNOS.
In fact, this is collaborated by the recent finding that
BACE1 expression was elevated in mice deficient in eNOS
[55]. Our data also suggest that PGC-1a, a crucial PPARg
coactivator in the transcriptional controls of gluconeogen-
esis and energy metabolism [56], may be the key factor
executing the effects of low NO, through the activated
cGMP-PKG signaling pathway. Since PGC-1a is the most
critical regulator in response to metabolic stress, it is
believed to play a key role in AD pathogenesis. Our find-
ing that PGC-1a is likely involved in BACE1 transcrip-
tional control provides the first molecular basis of a
metabolic signal/factor regulating an AD gene. In support
of this, PGC-1a expression was found to be reduced in
AD brains [57] and it was recently reported that PGC-1a
facilitates BACE1 protein degradation via the UPS [58,59].
Further characterization of the transcriptional network
involving PGC-1a, directly or indirectly, on BACE1 pro-
moter, will draw a fuller picture of the metabolic factors
regulating AD genes, which likely involve the entire
AMPK-SIRT1-PGC-1a pathway, in which NO signaling
plays an important role.
On the other hand, the high levels of NO-mediated
BACE1 inactivation via post-translational modification
in cultured neurons likely reflects the NO generated by
iNOS, known to elicit much higher NO production
(over 1,000-fold) compared with that generated by the
constitutive NOSs [37,38]. Inducible iNOS, shown to be
involved in the pathogenesis of AD, is activated under
inflammatory conditions and may upregulate BACE1 as
a result of activated NF-B and toxic peroxynitrite
formed by NO and superoxide anions. Although we
show that SNO-BACE1 is associated with reduced enzy-
matic activity, the elevated protein expression and enzy-
matic activity of BACE1 in late stages of AD may reflect
the dominant effect of severe oxidation by H2O2 and
peroxynitrite; it has been shown previously that lipid
oxidative products, such as 4-HNE, can upregulate
BACE1 transcriptionally [30].
H2O2-induced modification and S-nitrosylation repre-
sent the two dominant oxidative events modifying criti-
cal Cys residues in proteins. Interestingly, we observed
opposite effects from these two oxidative modifications
in BACE1 expression and activity. The interplay
between S-nitrosylation and H2O2-type oxidation of
BACE1 at the molecular level is not yet clear, albeit
both occur at certain critical Cys residues. Based on our
finding that NO supresses BACE1, we speculate that S-
nitrosylation and H2O2-type oxidation occur on overlap-
p i n gC y sr e s i d u e so nB A C E 1 ; nitrosylation precludes
further oxidation for enzymatic activation and thus
represents a self-defensive or house-keeping mechanism.
Among the 11 Cys residues on BACE1, it is known that
six Cys residues form three pairs of intramolecular dis-
ulfide bonds in mature BACE1 (Cys
216-420,C y s
278-443
and Cys
330-380; Figure 6A) which is essential for its
membrane-association and protein maturation but is
not required for its enzymatic activity [60]. Since the
pattern of BACE1 S-nitrosylation shows that it occurs
predominantly on the mature form of BACE1 (Figure
1A), we reason that the three pairs of Cys in the enzy-
matic pocket are not likely sites for nitrosylation.
Indeed, our preliminary study used site-directed muta-
genesis to analyze individual BACE1 mutants with each
Cys mutated to Ala and showed that Cys mutation at
the positions 216, 278, 330, 380, 420, 443, or 466 (the
membrane-proximal ones) resulted in lack of mature
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four Cys residues in the cytoplasmic tails, which are also
the S-palmitoylation sites, had different results; the
C483A mutant abolished mature BACE1, making it dif-
ficult to assess its contribution as a nitrosylation site;
Cys478A and Cys482A mutants appeared to show
reduced BACE1 nitrosylation and likely represent S-
nitrosylation sites under physiological conditions. It
should be pointed out that the results of this type of
semi-quantitative analysis are not sufficient to determine
the molecular basis of nitrosylation sites unambiguously.
In particular, the cytoplasmic tail has been reported to
be non-essential for the enzymatic activity of BACE1
[61,62], it remains unclear how the nitrosylation affects
BACE1 activity. Additional research to determine the
molecular basis of the nitrosylation and oxidation events
by quantitative mass spectrometry, as well as further
analysis of BACE1 and subcellular trafficking, localiza-
tion and distribution in lipid rafts using cell biology
approaches, are necessary to clarify the mechanism.
Conclusion
In summary, our studies have demonstrated that NO
exerts differential regulation on BACE1 at low and
modest to high concentrations, suppressing BACE1
transcriptionally or post-translationally through S-nitrosy-
lation, respectively. S-nitrosylation may represent a basic
regulatory mechanism for maintaining BACE1 at physiolo-
gical levels, outside of events that challenge the brain with
a wave of high oxidative stressors which upregulates and
activates BACE1. As BACE1 represents a favored thera-
peutic target for developing anti-AD agents, pharmacolo-
gical inhibitors of BACE1 have been actively pursued for
more than a decade. Despite significant progress, the
development of specific cell-permeable drugs that pene-
trate into the brain remains a challenge. Due to the recent
discouraging results from Eli Lilly’s trials on a g-secretase
inhibitor (Semagacestat/LY450139) showing worsening
cognitive performance in AD patients, efforts to discover a
novel mechanism to modulate secretases is of particular
importance. Further validation of the redox regulatory
mechanism of BACE1 may provide novel leads to modu-
late BACE1 by selectively targeting oxidized BACE1.
Methods
Cell culture, treatment of neurotoxic reagents and
transfection
Primary cultured cortical neurons (PRCN), neuroblas-
toma N2a cells and HEK 293 cells were prepared as
described [63]. N2a cells stably transfected with human
Figure 6 Mapping crucial cysteine residues for SNO-BACE1. (A) Schematic diagram of BACE1. BACE1 is a 501 amino-acid transmembrane
protein. Signal peptide (1-21 aa) and pro-peptide (22-45 aa) are cleaved during protein maturation. Within the lumenal domain there are two
active site motifs (signature sequences of aspartyl proteases) situated at amino acids 93-96 and 289-292, four N-glycosylation sites and six
cysteine residues involved in intramolecular disulfide bonds. The transmembrane domain is located between amino acids 461 and 477, and the
C-terminal part of the protein (24 aa) is located in the cytosol. (B) Site-directed mutagenesis data on the Cys mutants of BACE1. SNO-BACE1
levels were determined by biotin-switch assays and data were analyzed by densitometry of the SNO-BACE1/total BACE1 ratio to identify crucial
cysteine residues for s-nitrosylation of BACE1. Wild type and mutants of BACE1-HA expression plasmids were transfected into HEK293 cells. After
biotin-switch assay, SNO-BACE1 and total BACE1 proteins were probed with an anti-HA antibody.
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media supplemented with 400 μg/mL G418 (Sigma). For
the majority of experiments, freshly prepared SNOC
(Sigma-Aldrich, St. Louis, MO) was added at 100-200
μM to these cells for 30 or 60 min. SNOC was freshly
prepared as described [54]. In brief, to prepare a 100
mM stock solution, 0.0069 g sodium nitrite and 0.0121
g l-cysteine were added to 950 μlH 2O. Then, 50 μlo f
1 0 NH C li sa d d e dt oa d j u s tp Ht o7 . 4 .F o rA b25-35 pep-
tides (Bachem, Torrance, CA), neurons were treated for
4 hours before cell lysates were prepared. Transient
transfections were performed with plasmid constructs
for pCMV-HA-BACE1-WT and its site-directed muta-
genized constructs (Cysteine to Alanine substitution)
according to manufacturer’s protocol.
Human patient brains
Human brain samples were provided by UCSD, San
Diego, CA and were analyzed with institutional permis-
sion under California and National Institutes of Health
guidelines [Additional file 1]. Informed consent was
obtained following the procedures of the Institutional
Review Boards of the Sanford-Burnham Institute for
Medical Research.
Biotin-switch assay for detection of BACE1 S-nitrosylation
A biotin switch assay for detection of SNO-BACE1 was
performed as previously described with minor modifica-
tions [48]. PRCN, N2a or HEK293 cells were exposed to
various concentrations (0.01, 0.1, 10, 50, 100, 200 and
400 μM) of SNOC for 30 min. For calcium ionophore
(ionomycin), 1 μM of ionomycin was applied for 0-5-10-
15-30 min to neuronal cells.
Western blot analysis
SDS-PAGE gels and Western blots were performed as
described [64]. Samples were run on 10-20% Tricine
gels (Invitrogen) for Ab peptides and 4-20% Tris-Gly-
cine gels (Invitrogen) for regular SDS-PAGE analysis.
The following antibodies (Abs) were used in the present
study: mouse anti-HA Ab (Sigma); mouse anti-a-tubulin
Ab (Sigma, St. Louis, MO, USA); mouse anti-b-actin Ab
(Sigma); anti-mouse IgG and anti-rabbit IgG horseradish
peroxidase-conjugated Abs (Chemicon, Temecula, CA,
USA). In most of the experiments performed in the
early stages, we used the guinea pig antibody GP45
(Convance, Inc). Recently, we repeated some key experi-
ments with a specific monoclonal antibody (5D3)
derived from BACE1 deficient mice [9].
Fluorogenic BACE 1 activity assay
This assay was performed according to the company’s
protocol [64]. Briefly, cultured PRCN, N2a and
HEK293 cells were treated with or without SNOC and
H2O2 for the indicated time periods and homoge-
nized. The resulting aliquots (containing 15 μgo fp r o -
teins) were centrifuged at 13 000 × g for 15 min.
Then, the membrane pellets were recovered and incu-
bated at 37°C for 30 min in 50 μl of assay reaction
buffer (50 mM sodium acetate, pH 4.5; for a-secre-
tase, 10 mM Tris-HCl, pH 7.5) containing 10 μMs p e -
cific fluorogenic substrates. After incubation,
fluorescence was measured using a spectrometer at
excitation/emission wavelengths of 320/420 nm for
BACE-1.
Ab assays
Following various treatments, serum-free media was
conditioned for 4 hrs. Aliquots of conditioned media
were immunoprecipiated with 6E10 antibody and pro-
tein G/A beads to measure Ab peptides [65].
Quantitative RT-PCR on BACE1 and PGC-1 Messages
Total RNA was extracted using TRIzol reagent (Invitro-
gen). SuperScript First-Strand kit (Invitrogen) was used
to synthesize the first strand cDNA from samples with
an equal amount of RNA, according to the manufac-
turer’s instructions. Synthesized cDNAs were amplified
using RealMasterMix SYBR ROX (5 Prime) and Master-
cycler ep from Eppendorf with 3 min pre-incubation at
95°C followed by 40 cycles of 30 s at 95°C, 30 s at 55°C,
30 s at 72°C.;. The data were analyzed by using realplex.
PCR products were verified by melting curve analysis
and agarose gel electrophoresis. Rat bace1 primers [for-
ward 5’-TGGGTGAAGTCACCAATCAG-3’ and reverse
5’-CACTGGCCGTAGGTATTGCT-3’], human bace1
primers [ forward 5’-GCAGGGCTACTACGTGGAGA-
3’ and reverse 5’-GTATCCACCAGGATGTTGAGC-3’],
and rat pgc-1a primers [forward 5’-AAAGGGCCAAG
CAGAGAGA-3’ and reverse 5’-GTAAATCACACGG
CGCTCTT-3’] were used in the present studies. Primers
used for rat GAPDH, forward 5’-ACATTGTTGCCAT
CAACGAC-3’,r e v e r s e5 ’-CTTGCCGTGGGTAGCGT
CAT-3’; human GAPDH primers, forward 5’-AATCC
CATCACCATCTTCC-3’ and reverse 5’-GGACTCCAC
GACGTACTCA-3’. BACE1 and PGC-1 alpha mRNA
levels were normalized with the levels of GAPDH.
Luciferase assay for BACE1 promoter activity
1.5 Kb rat BACE1 promoter [63] and 2.2 Kb human
BACE1 promoter [19] in pGL3-Basic vector, together
with PGC-1a expression vector (Addgene), were trans-
fected into HEK 293 cells. pRL-SV40 containing the
Renilla luciferase gene (Promega) was cotransfected as
an internal control. 24 hours after transfection, cells
were collected in passive lysis buffer and analyzed with
the Dual luciferase reporter system (Promega) following
the manufacturer’s instructions.
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BACE1 mutants were created by site-directed mutagen-
esis (QuikChange
® II Site-Directed Mutagenesis Kits,
Stratagene, La Jolla USA) at C216, C278, C330, C380,
C420, C443, C466, C474, C478, C482, and C485 resi-
dues. The primers for C216A forward 5’-CTCCCTG
CAGCTTgctGGTGCTGGCTTCCC-3’ and reverse 5’-
GGGAAGCCAGCACCagcAAGCTGCAGGGAG-3’;C 2
78A forward 5’-CTGAAAATGGACgccAAGGAGTA
CAAC-3’ and reverse 5’-GTTGTACTCCTTggcGTC-
CATTTTCAG-3’; C330A forward 5’-GAGCAGCT
GGTGgccTGGCAAGCAGGC-3’ and reverse 5’-
GCCTGCTTGCCAggcCACCAGCTGCTC-3’; C380A
forward 5’-GTCCCAAGACGACgctTACAAGTTTGCC-
3’ and reverse 5’-GGCAAACTTGTAagcGTCGTC
TTGGGAC-3’; C420A forward 5’-GCTGTCAGCGCT
gccCATGTGCACGATG-3’ and reverse 5’-CATCGTG-
CACATGggcAGCGCTGACAGC-3’; C443A forward 5’-
GACATGGAAGACgctGGCTACAACATTC-3’ and
reverse 5’-GAATGTTGTAGCCagcGTCTTCCATGTC-
3’; C466A forward 5’-CATGGCTGCCATCgccGCC
CTCTTCATG-3’ and reverse 5’-CATGAAGAGGGC
ggcGATGGCAGCCATG-3’; C474A forward 5’-CAT
GCTGCCACTCgccCTCATGGTGTGTC-3’ and reverse
5’-CTGCTGGCGCAGggcGCGGAGGCAGCGC-3’;w e r e
utilized for PCR amplification. PCR amplification was
performed according to the company’s protocol.
Statistics
All quantitative data were presented as means ± SDV.
Comparisons between groups were analyzed with
unpaired ANOVA using Graphpad PRIZM software (La
Jolla, CA, USA) and values of p <0 . 0 5w e r ec o n s i d e r e d
to be significant.
Additional material
Additional file 1: The table of the patient cohort and information.
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